Clinical Trials Sponsored by Cristina Genzor

Total 1245 results

Cristina Genzor
Hospital Miguel Servet

Unknown

Basic Life Support by Children

Cardiopulmonary Arrest With Successful Resuscitation | Child, Only

Spain
Genor Biopharma Co., Ltd.

Recruiting

A Phase Ib Study of GB491 Plus Letrozole in Patients With Advanced Breast Cancer

Advanced Breast Cancer

China
Genor Biopharma Co., Ltd.

Recruiting

GB491 Combined With Fulvestrant for HR+ HER2- Locally Advanced or Metastatic Breast Cancer

Locally Advanced or Metastatic Breast Cancer

China
Genor Biopharma Co., Ltd.

Recruiting

A Study in Recurrent or Metastatic Cervical Cancer Patients With PD-L1 Positive

Cervical Cancer

China
Genor Biopharma Co., Ltd.

Recruiting

Clinical Trial in Chinese Patients of B-cell Non-Hodgkin's Lymphoma(GB226)

B-cell Non-Hodgkin's Lymphoma

China
Genor Biopharma Co., Ltd.

Recruiting

Clinical Trial in Chinese Patients of Elapsed/Metastatic/Unresectable Alveolar Soft Part Sarcoma(GB226)

Alveolar Soft Part Sarcoma

China
Genor Biopharma Co., Ltd.

Recruiting

Phase I Clinical Trial in Chinese Patients of Advanced and (or) Recurrent Solid Tumor/Lymphoma (GB226)

Lymphoma | Advanced Solid Tumor | Recurrent Solid Tumor | Recurrent Lymphocyte Depleted Classical Hodgkin Lymphoma

China
Genor Biopharma Co., Ltd.

Unknown

Phase I Clinical Study of GB222 to Evaluate the Safety, Tolerability and PK Profiles.

Brain Tumor

China
Genor Biopharma Co., Ltd.

Unknown

Phase Ⅰ Clinical Study Protocol of GB223 Monoclonal Antibody Injection

Bone Tumor

China
Genor Biopharma Co., Ltd.

Recruiting

A Study of GB491 in Combination With Letrozole in Patients With HR Positive and HER2 Negative Advanced Breast Cancer

Breast Cancer

China
Genor Biopharma Co., Ltd.

Recruiting

A Safety, Tolerability, PK and Preliminary Activity Study of GB263T in Advanced NSCLC and Other Solid Tumor

NSCLC | Other Solid Tumors

Australia
Genor Biopharma Co., Ltd.

Recruiting

Clinical Study of Recombinant Anti-HER2 Humanized Monoclonal Antibody for Injection

HER2-positive Breast Cancer

China
Genor Biopharma Co., Ltd.

Completed

Clinical Trial of Comparative Study of GB221 Pharmacokinetics

Metastatic Breast Cancer

Australia
Genor Biopharma Co., Ltd.

Unknown

A Study to Evaluate the Safety and Tolerability of Multiple Doses of Gerilimzumab in Rheumatoid Arthritis Patients

Rheumatoid Arthritis

China
Genor Biopharma Co., Ltd.

Unknown

Clinical Study of Recombinant Anti-HER2 Humanized Monoclonal Antibody (GB221) for Injection

HER-2-positive Advanced Breast Cancer

China
Hospital Universitario Infanta Cristina

Completed

Usefulness of Lidocaine as Topical Pharyngeal Anaesthesia in Esophagogastroduodenoscopy Under Sedation With Propofol

Esophagogastroduodenoscopy

Spain
Genor Biopharma Co., Ltd.

Recruiting

A Safety, Tolerability, Pharmacokinetics and Efficacy Study of GB261 in B-Cell NHL and CLL.

CLL | B Cell NHL

Australia
Genor Biopharma Co., Ltd.

Recruiting

Clinical Trial in Chinese Patients of Relapsed and Refractory Peripheral T Cell Lymphoma (GB226)

Peripheral T Cell Lymphoma

China
Genor Biopharma Co., Ltd.

Completed

A Study of [14C]GB491 in Male Healthy Subjects

Breast Cancer | Nonsmall Cell Lung Cancer

China
Genor Biopharma Co., Ltd.

Completed

Single Dose Pharmacokinetic Study of GB221 in Comparison With Herceptin ®

Breast Cancer

China
Genor Biopharma Co., Ltd.

Unknown

Phase Ⅰ Clinical Trial of Gerilimzumab Injection in Healthy Subjects

Rheumatoid Arthritis

China
Genor Biopharma Co., Ltd.

Unknown

Clinical Comparative Study to Evaluate the Efficacy and Safety of Recombinant Anti-TNF-alpha Antibodies for Injection

Rheumatoid Arthritis

China
Genor Biopharma Co., Ltd.

Unknown

Clinical Trial in Chinese Healthy Volunteers of GB222

Non-small Cell Lung Cancer

China
Xencor, Inc.

Terminated

Phase 2 Study of Plamotamab Combined With Tafasitamab Plus Lenalidomide Versus Tafasitamab Plus Lenalidomide in R/R DLBCL

Diffuse Large-cell B-cell Lymphoma

Spain, United States, France
Hospital Universitario Infanta Cristina

Completed

Resection of the Inferior Vena Cava Due to Tumor Involvement (CAVARESECT)

Vascular Diseases | Neoplasms | Surgery--Complications | Vein Disease

Spain
Hospital Universitario Infanta Cristina

Unknown

The Titan Versus Everolimus Intracoronary Stent (Xience V) in Diabetic Patients (TITANIC-XV)

Diabetes Mellitus | Percutaneous Coronary Intervention

Spain, Finland
Xencor, Inc.

Recruiting

Study of Vudalimab or Pembrolizumab in Combination With Chemotherapy as First-line Treatment in Patients With Advanced NSCLC

Nonsquamous Non-small Cell Lung Cancer

United States
Xencor, Inc.

Recruiting

A Study of XmAb®662 as Monotherapy or in Combination With Pembrolizumab in Advanced Solid Tumors

Solid Tumors

United States
Xencor, Inc.

Recruiting

Phase 1, First-in-human, Dose-finding and Expansion Study to Evaluate XmAb®808 in Combination With Pembrolizumab in Advanced Solid Tumors

Colorectal Cancer | Castration-resistant Prostate Cancer | Head and Neck Squamous Cell Carcinoma | Urothelial Carcinoma | Ovarian Cancer, Epithelial | TNBC - Triple-Negative Breast Cancer | Renal Cell Carcinoma, Clear Cell | Melanoma Excluding Uveal Melanoma | Non-small Cell Lung Cancer, Squamous or...

United States
Xencor, Inc.

Recruiting

XmAb®20717 (Vudalimab) Alone or in Combination With Chemotherapy or Targeted Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer

Metastatic Castration-Resistant Prostate Cancer

United States
Xencor, Inc.

Completed

Safety Study of XmAb®2513 to Treat Hodgkin Lymphoma or Anaplastic Large Cell Lymphoma

Hodgkin Lymphoma | Anaplastic Large Cell Lymphoma

United States
Xencor, Inc.

Completed

Safety and Tolerability of XmAb®5574 in Chronic Lymphocytic Leukemia

Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma

United States
Ventor Technologies

Unknown

Transapical Implantation of Ventor Embracer™ Valve in Patients With Severe Aortic Valve Disease

Aortic Valve Disease

Germany
TenNor Therapeutics Limited

Completed

TNP-2092 to Treat Acute Bacterial Skin and Skin Structure Infection (P2_ABSSSI)

Gram-Positive Bacterial Infections | Skin and Subcutaneous Tissue Bacterial Infections

United States
Xencor, Inc.

Recruiting

Phase 1, Safety and Tolerability Study of XmAb®541 in Advanced Solid Tumors

Testicular Germ Cell Tumor | Ovarian Cancer | Endometrial Cancer | Ovarian Germ Cell Tumor | Germ Cell Tumor

United States
Xencor, Inc.

Recruiting

Multiple Ascending-Dose Study of XmAb®27564 in Patients With Psoriasis or Atopic Dermatitis

Psoriasis | Atopic Dermatitis

United States
Xencor, Inc.

Recruiting

Study of XmAb®819 in Subjects With Advanced Clear Cell Renal Cell Carcinoma

Clear Cell Renal Cell Carcinoma

United States
Geneos Therapeutics

Active, not recruiting

GNOS-PV02 Personalized Neoantigen Vaccine, INO-9012 and Pembrolizumab in Subjects With Advanced HCC

HCC

United States, New Zealand
Xencor, Inc.

Terminated

Study Evaluating AMG 424 in Subjects With Multiple Myeloma

Relapsed/ Refractory Multiple Myeloma

United States, Australia
Xencor, Inc.

Completed

Safety and Tolerability of XmAb®7195 in Adult Healthy Volunteers and Adult Subjects With a History of Allergic Rhinitis and/or Allergic Conjunctivitis and/or Atopic Dermatitis

Allergic Rhinitis | Atopic Dermatitis | Allergic Conjunctivitis

United States
TenNor Therapeutics (Suzhou) Limited

Completed

Human Mass Balance and Biotransformation Study of [14C]TNP-2198

Helicobacter Pylori Infection

China
TenNor Therapeutics (Suzhou) Limited

Completed

Safety, Tolerability, Pharmacokinetic Characteristics and Preliminary Efficacy of TNP-2092 Capsules in Liver Cirrhosis Patients With Hyperammonemia

Hyperammonemia

China
TenNor Therapeutics (Suzhou) Limited

Completed

Efficacy and Safety of Rifasutenizol (TNP 2198) in Participants With H. Pylori Infection

H.Pylori Infection

China
TenNor Therapeutics (Suzhou) Limited

Completed

A Phase 1, Single-center, Double-blind, Placebo-controlled Study of TNP-2092 Capsules, and the Food Effect Study After Single-dose Oral Administration of TNP-2092 Capsules

Hyperammonemia

China
TenNor Therapeutics (Suzhou) Limited

Completed

Efficacy and Safety After Multiple Doses of TNP-2198 Capsules, Rabeprazole Sodium Enteric-coated Tablets and Amoxicillin Capsules in Helicobacter Pylori Infected-positive Participants

Helicobacter Pylori Infection

China
TenNor Therapeutics (Suzhou) Limited

Completed

A Study to Evaluate Preliminary Helicobacter Pylori Eradication After Multiple Doses of TNP-2198 Capsules Combined With Rabeprazole Sodium Enteric-coated Tablets, or Rabeprazole Sodium Enteric-coated Tablets and Amoxicillin Capsules

Helicobacter Pylori Infection

China
TenNor Therapeutics (Suzhou) Limited

Completed

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Food Effect of TNP-2198 Capsules After Single Oral Dose in Healthy Participants

Helicobacter Pylori Infection

China
Christina Murphey, RN, PhD

Terminated

Efficacy of CES in New Mothers During the Post Partum Period

Depression | Insomnia | Anxiety | Sleep Quality

United States
TenNor Therapeutics (Suzhou) Limited

Completed

A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of TNP-2198 Capsules in Asymptomatic Participants With Helicobacter Pylori Infection

Helicobacter Pylori Infection

China
Christina Murphey, RN, PhD

Suspended

New Mothers Alpha-Stim

Depression | Insomnia | Anxiety | Sleep Quality

United States

3

Subscribe